Meliora Tx is committed to bringing a new approach to oncology drug dev.
This example from @JSheltzer's lab demonstrates why identifying drug MOA's at scale is incredibly powerful - and necessary!
New from my lab: we show that a clinical-stage oncology drug from Eli Lilly is mischaracterized, and its true anti-cancer target is EGFR. We also show how in vitro drug assays can be misleading - cellular+genetic methods are needed to determine drug MOAs.
https://t.co/xEhKNQHtMb
Exclusive look at the pitch deck @MelioraTx used to raise its $11 million seed round to find and develop better cancer treatments through its ML/AI tech platform
https://t.co/z6mZck59Ye
Proud to announce the launch of Meliora Therapeutics, a mechanism-focused drug development company, co-founded with @davidycli and @joans, with $11M in seed funding from @HOFCapital, @obviousvc, @Zhenfund, @villageglobal, and others.
https://t.co/zgZ5whecJI
We are thrilled to share our $11M seed financing with participation from @HOFCapital, @obviousvc , @ZhenFund , @AmericanCancer's BrightEdge, @villageglobal, & others.
We believe that the future of cancer drugs will be mechanism focused development.
https://t.co/KkSRGy7Y7Y
1/ I'm thrilled to share what we've been working on for the past year @MelioraTx !
Meliora believes the future of oncology drug development will be mechanism based.
https://t.co/TKanZraDKF
Today @MelioraTx came out from the stealth with an announcement of $11M seed round. We are proud to back such a visionary team @davidycli @JSheltzer @Joans with incredible investors @HOFCapital @ZhenFund and others https://t.co/IzML6w65ZX